Expert Opin Pharmacother. 2025 Nov 30. doi: 10.1080/14656566.2025.2597993. Online ahead of print.
ABSTRACT
INTRODUCTION: Gout is the most common inflammatory arthritis in adults in the U.S. and worldwide. Men are affected more than women, and cardiometabolic diseases frequently accompany this condition.
AREAS COVERED: In this review, we focus on evidence related to the risk of cardiovascular disease (CVD) and cardiovascular mortality in people with gout. We examine role of treatments for gout in reducing CV risk.
EXPERT OPINION: Gout, as a prototype of systemic inflammatory conditions, is associated with joint and systemic inflammation. Gout is an independent risk factor for coronary artery disease, myocardial infarction (AMI) and atrial fibrillation (AF), among other CVD, and death. Urate lowering therapy (ULT), in particular, allopurinol is associated with a lower risk of AMI, AF and other CV outcomes in people with gout. Colchicine use is associated with reduced acute CV events both in general population with CAD and in gout. Treat-to-target (T2T) serum urate approach entails titrating ULT by monitoring serum urate levels and gout flares. Allopurinol, the most commonly used and inexpensive ULT, in approved daily doses of 300-800 mg can achieve target serum urate less than 6 mg/dl or 5 mg/dl.
PMID:41320643 | DOI:10.1080/14656566.2025.2597993